JPRN-jRCTs032200108
Completed
Phase 1
Clinical research to confirm the safety of bone regenerationpromoting materials based on type 1 collagen - Synthetic bone graft substitute transplantation for the socket preservation
Tobita Morikuni0 sites0 target enrollmentSeptember 7, 2020
ConditionsSocket preservation
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Socket preservation
- Sponsor
- Tobita Morikuni
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
/A
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients who perform tooth extraction on the premise of the dental implant treatment
Exclusion Criteria
- •\-Active generalized periodontal disease; evident periapical radiolucencies or abscesses
- •\-autoimmune disorders; taking or having a history of bisphosphonate medications or Denosumab (history of MRONJ (medication\-related osteonecrosis of the jaw)/BRONJ (bisphosphonate\-related osteonecrosis of the jaw))
- •\-Current taking methotrexate(MTX) or steroids.
- •\-Congenital or metabolic bone disorders; or uncontrolled diabetes.
- •\-Current or former smoker or user of chewing tobacco or nicotine\-containing products
- •\-Females who are pregnant, breastfeeding, or are planning to conceive during their enrollment in the clinical investigation.
- •\-History of any severe allergic or anaphylactic reactions to collagen or gelatin, or current sensitivity to collagen or gelatin.
- •\-Have a history of complicate malignant tumor.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Safety investigations for the bone regenerative medicine using growth factors secreted from the patients' own stem cellsBone defects due to removal of teeth, PeriodontitisJPRN-UMIN000011286agoya University10
Not yet recruiting
Not Applicable
Clinical study for efficacy and safety of bone marrow derived cell concentrate and allogenic dermal matrix complex therapy in diabetic foot ulcerEndocrine, nutritional and metabolic diseasesKCT0009122Soon Chun Hyang University Hospital Bucheon58
Completed
Phase 1
Safety and Efficacy of Autologous Bone Marrow Mononuclear Cells in Patients With Severe Critical Limb IschemiaCritical Limb IschemiaNCT01472289TotipotentSC Scientific Product Pvt. Ltd.17
Withdrawn
Phase 3
Bone Healing Accelerant Versus Standard of Care for Open Tibia FracturesTibial FracturesNCT03826784Carmell Therapeutics Corporation
Withdrawn
Phase 2
Multiregion BHA in Open Tibia FracturesTibial FracturesNCT04056429Carmell Therapeutics Corporation